The key role of plasmid DNA in therapeutic applications

Thanks to its safety profile, manufacturing accessibility, stability and versatility, plasmid DNA is increasingly used across multiple therapeutic fields.

Three main therapeutic strategies rely on plasmid DNA, differing in both the purpose of expressed protein and the method of administration.

Main therapeutic strategies

1. Gene therapy uses plasmid DNA to supply a functional gene directly to patient tissues. In gene therapy, plasmid DNA is the source of the gene that enables cells to produce a therapeutic protein that replaces a missing or defective one or modulates a dysregulated pathway.

2. DNA vaccines rely on plasmid DNA to encode an antigen that stimulates immunity. After the cell nucleus entry, the encoded gene is converted into messenger RNA and then translated into the antigenic protein. The immune system detects this protein as foreign and responds through both antibody production and T cell activation.

3. Cell therapy applies plasmid DNA ex vivo to modify immune or stem cells before they are returned to the patient. By introducing genes that encode receptors, cytokines, or regulatory elements, plasmid DNA enables targeted and reversible adjustments to cellular behavior, shaping how these cells function once administered.

In conclusion, these three approaches share a common molecular tool but yield different therapeutic objectives and delivery routes.

What are the advantages of using plasmid DNA across these therapeutic modalities?

Gene therapy, DNA vaccination and cell therapy all benefit from the ability of plasmid DNA to deliver genetic information in a safe and controlled manner. Several common features explain why pDNA is valuable across such different applications. Plasmid DNA is noninfectious, does not contain viral components which avoid safety concerns associated with viral vectors. It also carries a very low probability of integrating into the host genome limiting concerns related to insertional mutagenesis.

Plasmids are easy to engineer, compatible with microbial manufacturing and suitable for large scale GMP production¹.

Plasmid DNA is chemically stable and supports long term storage without strict temperature requirements. This facilitates global distribution. pDNA constructs can accommodate large genes or multiple regulatory elements and remain suitable for repeated administration because the immune system does not develop strong vector specific immunity. These combined properties underpin the broad utility of plasmid DNA in therapeutic development.

The shared challenge: achieving effective cell delivery

Despite their strengths, plasmid DNA vaccine based (direct injection) approaches share a fundamental challenge: getting the plasmid to the right cells and ensuring that it reaches the nucleus. Several biological barriers complicate this process, including degradation at the administration site, limited uptake by the intended cells and the need to escape endosomal pathways once inside the cytoplasm. Whether the objective is to express a therapeutic protein in muscle, generate an antigen for vaccination or engineer cells outside the body, plasmid DNA must successfully navigate these barriers to be effective.

To address these limitations, multiple delivery strategies are under investigation.

1. Injection methods

Several injection methods show promising results for the delivery of plasmid DNA.

- Electroporation temporarily increases membrane permeability and enhances intracellular uptake².

- Microneedle devices place plasmid DNA directly into immune active skin layers and provide a minimally invasive route of administration³.

- Gene gun delivers plasmid DNA by propelling DNA coated metal particles into target tissues using a burst of pressure. This approach facilitates direct entry of the plasmid into cells.⁴

- Jet injection is a needle free method that uses a high-pressure fluid stream to drive plasmid DNA through the skin. It improves tissue distribution and cellular uptake, as seen with the authorized ZyCoV D COVID 19 DNA vaccine^4,5.

2. Carriers

Beyond injection techniques, researchers are also evaluating a range of delivery carriers.

- Lipid based formulations protect plasmid DNA and promote membrane fusion⁶.

- Polymer carriers offer stability and can be designed for tissue specific targeting⁷.

- Exosomes are also being explored as natural carriers for genetic material. Their biocompatibility and efficient fusion with target cells make them a promising option for enhancing plasmid DNA delivery with limited immune activation.⁸

Continued progress in these technologies aims to strengthen cellular uptake, improve nuclear access and expand the clinical use of plasmid DNA based therapeutics. This shared limitation, combined with the advantages of plasmid DNA described above, shapes how plasmid DNA is implemented across each therapeutic field.

What are the promising clinical applications of these therapies?

1. Clinical explorations for pDNA gene therapy

Plasmid-based gene delivery has been investigated across a wide spectrum of therapeutic areas, including muscular disorders⁹, metabolic diseases¹⁰, and vascular conditions¹¹.

Clinical development programs illustrate this versatility. Examples include plasmids expressing vascular endothelial growth factor for critical limb ischemia, hepatocyte growth factor for diabetic neuropathy, and constructs evaluated for amyotrophic lateral sclerosis or Duchenne muscular dystrophy¹². In oncology, plasmid DNA encoding cytokines for localized immune stimulation has also advanced into clinical evaluation¹³.

2. Clinical progress for vaccine DNA

For now, one DNA vaccine for human use has been authorized for emergency use: ZyCoV D, a SARS CoV 2 vaccine approved for emergency use in India It became the first human DNA vaccine approved for emergency use, confirming that DNA based immunization can be effective in people⁴.  

Multiple DNA vaccines have already advanced to clinical evaluation. Examples include INO 4800 for SARS CoV 2, which has reached late stage trials¹⁴, GLS 5700 for Zika virus¹⁵, and VGX 3100 for precancerous lesions linked to human papillomavirus¹⁶. Additional candidates are being tested for HIV, hepatitis B, and melanoma^17–19. This growing clinical pipeline demonstrates the versatility of DNA vaccination and its relevance for both infectious diseases and cancer therapy.

DNA vaccines have shown even stronger progress in veterinary medicine, where several products are already licensed. Their success highlights the robustness of plasmid-based vaccination platforms in real world settings

3. Clinical perspectives for plasmid cell therapy

Cell therapy is central to emerging immunotherapies, where T cells or natural killer cells can be endowed with new recognition patterns to detect diseased or malignant cells^20,21.

Plasmid is also explored for regenerative medicine, where it is increasingly used to supply genes that promote tissue repair, support cellular differentiation or enhance local healing processes. Non-viral plasmid delivery has been explored to drive the production of growth factors such as BMP-2, BMP-6 or FGF-2, which are known to stimulate bone formation, vascularization or cartilage regeneration. When combined with stem cells or biomaterial scaffolds, plasmid DNA can create a microenvironment that encourages damaged tissues to rebuild themselves. This ability to deliver therapeutic signals without relying on viral vectors’ positions plasmid DNA as a flexible and safer alternative for regenerative strategies, from musculoskeletal repair to emerging tissue-engineering applications.²²

What does the future hold for plasmid DNA therapies?

New plasmid formats, improved regulatory elements, and refined delivery technologies are steadily broadening the therapeutic potential of plasmid DNA. Current development efforts include designing smaller plasmid backbones to enhance expression efficiency and updating promoter architectures for more precise control of gene activity. In parallel, the introduction of molecular stimulators has been shown to increase antigen production in treated tissues.

Researchers are also exploring combinations of plasmid DNA with immune modulators, synthetic promoters, and personalized antigen sequences to achieve more tailored and potent responses. Advances in delivery are contributing significantly as well: needle-free administration, targeted carriers, and next-generation adjuvants all aim to increase both efficiency and patient accessibility.

Together, these innovations reflect only a fraction of the momentum in the field. They collectively reinforce plasmid DNA as a stable, versatile, and increasingly sophisticated platform for advanced therapeutic development.

Need a supplier of GMP plasmid DNA?

As therapies progress from research to clinical use, GMP grade plasmid DNA becomes essential. High quality manufacturing ensures that plasmid DNA meets strict standards for purity, identity and consistency. At Eurogentec, plasmid DNA is produced under validated GMP conditions to support safe and reliable therapeutic development. Our long-standing expertise helps partners translate innovative genetic concepts into clinical ready materials that meet international regulatory expectations.

Learn more about our services => GMP Plasmid DNA Manufacturing - CDMO since 1994 | Eurogentec

Frequently Asked Questions (FAQs)

1. How does plasmid DNA differ from mRNA therapeutics?
   While mRNA provides fast but short-term expression in the cytoplasm, plasmid DNA offers longer-lasting expression after reaching the nucleus. This makes plasmid DNA suitable for sustained therapeutic effects and stable storage.
2. Why is GMP grade plasmid DNA important for clinical use?
   GMP grade plasmid DNA ensures consistency, purity, and regulatory compliance. It is essential for safe and reliable manufacturing of plasmid-based products used in human therapies and clinical trials.
3. What future developments are shaping plasmid DNA applications?
   New approaches include combining plasmid DNA with immune checkpoint inhibitors, developing personalized DNA vaccines, and exploring needle free and targeted delivery systems to enhance therapeutic precision and patient comfort.
4. What is the difference between a classical plasmid and a mini-backbone plasmid?

A classical plasmid is a standard DNA vector that contains several kilobases of bacterial backbone sequences, including an origin of replication, an antibiotic-resistance gene and other elements required for propagation in E. coli. This format is well-established, easy to produce and widely used for GMP-grade plasmid DNA manufacturing.

A mini-backbone plasmid (also called minimal plasmid, small-backbone plasmid or next-generation plasmid) significantly reduces non-essential bacterial sequences and often replaces antibiotic selection with an antibiotic-free system. Because the backbone is much smaller, these plasmids can offer higher plasmid yield, improved supercoiled DNA percentage and better transfection efficiency for applications such as viral vector production or mRNA manufacturing.

In summary:
Classical plasmids provide robustness and broad compatibility, while mini-backbone plasmids offer a compact, streamlined design that can enhance productivity and performance in modern gene-therapy and vaccine workflows.

5. Why is plasmid DNA considered a safer alternative to viral vectors in some therapies?

Plasmid DNA is nonviral, noninfectious and shows a very low likelihood of integrating into the genome, reducing the risk of insertional mutagenesis. It can carry large genetic payloads and be rapidly engineered without the complex safety constraints associated with viral vector production.

6. Are smaller or “mini-backbone” plasmids improving clinical plasmid applications?

Mini-backbone plasmids remove nonessential bacterial sequences and often use antibiotic-free systems, resulting in improved manufacturing yield, higher supercoiled DNA content and more efficient expression. They are increasingly explored in DNA vaccines, mRNA production and gene-therapy platforms.

References

1. Neeli, P., Chai, D., Roy, D., Prajapati, S. & Bonam, S. R. DNA Vaccines in the Post-mRNA Era: Engineering, Applications, and Emerging Innovations. Int. J. Mol. Sci. 26, 8716 (2025).
2. Lee, S.-H., Danishmalik, S. N. & Sin, J.-I. DNA vaccines, electroporation and their applications in cancer treatment. Hum. Vaccines Immunother. 11, 1889–1900 (2015).
3. Fan, F. et al. Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants. Emerg. Microbes Infect. 12, 2202269 (2023).
4. Pagliari, S., Dema, B., Sanchez-Martinez, A., Montalvo Zurbia-Flores, G. & Rollier, C. S. DNA Vaccines: History, Molecular Mechanisms and Future Perspectives. J. Mol. Biol. 435, 168297 (2023).
5. Miyazaki, H. et al. Mechanism of jet injector-induced plasmid DNA uptake: Contribution of shear stress and endocytosis. Int. J. Pharm. 609, 121200 (2021).
6. Cui, L. et al. Efficient Delivery of DNA Using Lipid Nanoparticles. Pharmaceutics 14, 1698 (2022).
7. Mashal, M. et al. Stability of polymeric cationic niosomes and their plasmid DNA-based complexes as gene delivery carriers. Drug Deliv. 30, 2219420 (2023).
8. Wallen, M., Aqil, F., Spencer, W. & Gupta, R. C. Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy. Pharmaceutics 15, 1832 (2023).
9. Bertoni, C. et al. Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc. Natl. Acad. Sci. 103, 419–424 (2006).
10. Moscoso, C. G. & Steer, C. J. The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases. Genes 11, 915 (2020).
11. Shimamura, M., Nakagami, H., Sanada, F. & Morishita, R. Progress of Gene Therapy in Cardiovascular Disease. Hypertension 76, 1038–1044 (2020).
12. Luís, M. A. et al. Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives. Pharmaceutics 17, 104 (2025).
13. Ferrone, C. R. et al. Adjuvanticity of Plasmid DNA Encoding Cytokines Fused to Immunoglobulin Fc Domains. Clin. Cancer Res. 12, 5511–5519 (2006).
14. Jia, S. et al. Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial. Hum. Vaccines Immunother. 21, 2448405 (2025).
15. Tebas, P. et al. Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine. N. Engl. J. Med. 385, (2021).
16. Bhuyan, P. K. et al. Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL. Hum. Vaccines Immunother. 17, 1288–1293 (2021).
17. Hokello, J., Sharma, A. L. & Tyagi, M. An Update on the HIV DNA Vaccine Strategy. Vaccines 9, 605 (2021).
18. Beretta, M. et al. Enhanced hepatitis B virus–specific immunity by combining neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B virus infection. Hepatology 82, 470–486 (2025).
19. Rezaei, T. et al. Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res. 34, 869–891 (2021).
20. Prazeres, P. H. D. M. et al. Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells. Int. J. Nanomedicine Volume 18, 5891–5904 (2023).
21. Matosevic, S. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. J. Immunol. Res. 2018, 1–20 (2018).
22. Hosseinkhani, H., Domb, A. J., Sharifzadeh, G. & Nahum, V. Gene Therapy for Regenerative Medicine. Pharmaceutics 15, 856 (2023).